Author information unavailable
Abstract
Open-access reader
Abstract Separate trials report strikingly positive results for idelalisib and ibrutinib in the treatment of patients with chronic lymphocytic leukemia, leading some researchers to suggest that patients could rely on targeted therapies and forego chemotherapy.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Abstract Separate trials report strikingly positive results for idelalisib and ibrutinib in the treatment of patients with chronic lymphocytic leukemia, leading some researchers to suggest that patients could rely on targeted therapies and forego chemotherapy.
Key concepts: Ibrutinib, Idelalisib, Chronic lymphocytic leukemia, Bruton's tyrosine kinase, Lymphocytic infiltration, Leukemia, Oncology, Medicine